Market Overview

UPDATE: Bank of America Cuts PO to $24 on VIVUS on Sluggish Qsymia Launch

Related VVUS
Neothetics' Fat Reduction Candidate Fails in Phase II Study
Why is Catalyst Pharmaceuticals' Stock Up 160% this Year?

Bank of America maintained VIVUS (NASDAQ: VVUS) with a Buy rating and lowered the price onjective from $26.00 to $24.00.

Bank of America noted, "VVUS reported 4Q Qsymia sales of $2mn vs. our $2.5mn est. and reported higher than expected SG&A, driven by Qsymia launch costs. We expect this expense level could continue, given education requirements and potential for expansion to DTC advertising later in 2013. We raised our SG&A expense est. for 2013 to $190mn (from $150mn). We also trimmed our 2013 US Qsymia sales est. to $60mn (from $70mn) as we expect impact from a positive FDA decision on retail access to now be more weighted in 2H13."

VIVUS closed at $12.41 on Monday.

Latest Ratings for VVUS

Feb 2016RBC CapitalDowngradesOutperformSector Perform
Nov 2014Bank of AmericaMaintainsUnderperform
May 2014JP MorganMaintainsNeutral

View More Analyst Ratings for VVUS
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Analyst Ratings


Related Articles (VVUS)

View Comments and Join the Discussion!